NOKOMIS, Fla.--(BUSINESS WIRE)--

The awarding of the Nobel Prize this week to two scientists who have revolutionized stem cell research could lead to an influx of investment capital into the industry, said Rainbow Coral Corp. (RBCC) CEO Patrick Brown on Wednesday.

Japans Shinya Yamanaka and Britain's John Gurdon were jointly awarded the medicine prize for proving that adult cells can be regressed back into stem cells, creating cells known as induced pluripotent stem cells (iPS) that allow for stem-cell research that doesnt necessitate the destruction of a fetus.

The tremendous recognition of this groundbreaking research that the Nobel Prize brings could spark a host of medical breakthroughs, investment interest and business developments in the stem cell field, Brown said. Its a very exciting time to be part of a young company striving to grow alongside this explosive industry.

Wire service AFP reported this week that Yamanaka will likely get up to 30 billion yen ($383 million) for his stem cell research over the next decade. RBCC is currently working to help speed up the research of Yamanaka and others into potential cures for deadly diseases by commercializing the use of a groundbreaking new technology in select markets around the world. The company has engaged Regenetech in discussions regarding the potential acquisition of a license to perform cell expansion using that companys Rotary Cell Culture SystemTM.

RBCC plans to offer the new technology to help kickstart billions of dollars worth of research in an industry currently dominated by Amgen, Inc. (AMGN), Celgene Corporation (CELG), Genzyme Corp. (NASDAQ:GENZ) and Gilead Sciences Inc. (GILD).

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [http://www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit http://www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Read the original here:
RBCC: Nobel Prize Could Bring Big Investments in Stem Cell Research